This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Majority of bone fractures are due to osteoporosis i.e. lwo bone mass. In rare cases, however, bone fragility is present despite normal or high bone mass and may be due to low bone turnover. This study aims to define the effects of rhPTH (recombinant human parathyriod hormone) therapy both acutely, on calcium balance, and chronically, on bone turnover, bone density and bone microarchitecture, in patients who have lwo trauma fractures and don not have osteoporosis or other known forms of metabolic bone disease. The hypothesis is that in conditions where increased fragility is associated with normal or high bone mass and low bone turnover, treatment with an agent that stimulates bone turnover will improve the biological quality of the bone and decrease fragility.
The specific aims are to 1. Decscribe the acute effects of rhPTH administration on calcium balance; and 2. Examine the effect of 12 months of therapy with rhPTH on bone density, bone turnover and bone micro-architecture.
Showing the most recent 10 out of 244 publications
